
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines.
JSR Life Sciences provides specialized technology, products, materials, and services to biopharmaceutical companies and life science researchers. Through the service offerings of its affiliates, JSR has created a framework that provides a fully integrated drug development process, from discovery through commercial production, that can accelerate development timelines and increase clinical success rates.
For more than 20 years, Selexis has helped its partners predictably, rapidly and cost-effectively generate life-saving biologic medicines and vaccines. Its SUREtechnology Platform™ is being used by global partners, resulting in nearly 150 biologic drug candidates in clinical development and nine products in commercial manufacturing. Selexis is able to generate stable and high-expressing (up to 10 g/L in bioreactor*) research cell banks (RCBs) in as little as 8–12 weeks.
At Selexis, diversity, inclusion, and equality have been a part of our DNA since our founding. Having varied perspectives drives innovation, impacts our products and services, and helps us better serve our partners and employees. While we have more work to do to advance diversity and inclusion, we are constantly growing, learning, and iterating to move our company forward.
The Selexis SURE CHO-M Cell Line is a proprietary high-performance mammalian cell line that is derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies. The growth and production properties of the Selexis SURE CHO-M Cell Line are well defined, and the feed strategy has been optimized, allowing for faster and more efficient scale-up to bioreactors. Therapeutics that have been generated using Selexis SURE CHO-M cells include more than 140 clinical trial, as well as 8 marketed products across a range of indications.
Solutions for complex human diseases are being addressed with increasingly complex protein therapeutic modalities. These include molecules such as bispecific proteins, DARPins, triabodies and novel scaffolds decorated with peptides, enzymes or growth factors, to name a few. Many, if not most, of these proteins do not exist in nature and producing them presents a range of production and secretion challenges such as ensuring appropriate folding and subunit pairing.
In 2021, Selexis surveyed our partners to collect feedback and gain insight about our company and technology. With our partners’ insights, we can build upon our business, continue to advance our technology and enhance our overall partner experience.
In 2019, Selexis surveyed our partners to collect feedback and gain insight about our company and technology. With our partners’ insights, we can build upon our business, continue to advance our technology and enhance our overall partner experience.
Trust develops when credibility, respect and fairness thrive in a workplace. A culture of trust gives rise to camaraderie and pride. The survey uses 58 closed questions in the Trust-Index employee survey to find out how employees see the following dimensions in their company….
In 2017, Selexis surveyed our partners to collect feedback and gain insight about our company and technology. With our partners’ insights, we can build upon our business, continue to advance our technology and enhance our overall partner experience.
The Contract Development Manufacturing Organization of the 21st CenturyCombined Forces to Serve as the Biopharmaceutical Customer- and Patient-Focused CDMO with the Most Robust and Fastest “Gene to GMP” Service Offering in the Industry
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 158 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Copyright© 2022 Selexis SA. All Rights Reserved.